Charlene D Fell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10423349/publications.pdf

Version: 2024-02-01

28	917	687363 13	580821 25
papers	citations	h-index	g-index

29	29	29	951
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 832-837.	5.6	220
2	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 151, 619-625.	0.8	177
3	The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 402-407.	5.6	98
4	Pulmonary Manifestations of Systemic Lupus Erythematosus. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 249-254.	2.1	70
5	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	6.7	57
6	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities. Clinics in Chest Medicine, 2012, 33, 51-57.	2.1	53
7	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	45
8	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	3.2	37
9	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.8	25
10	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	3.6	18
11	Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 127-137.	1.9	16
12	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	3.2	16
13	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.5	15
14	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.8	14
15	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	2.3	12
16	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.5	8
17	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 153, 85-90.	2.9	7
18	Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 71-76.	0.5	5

#	Article	IF	Citations
19	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5
20	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	3.6	5
21	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668.	3.2	4
22	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.5	3
23	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	2.9	3
24	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867.	3.2	2
25	PREDICTING IPF VS NSIP WITHOUT A SURGICAL LUNG BIOPSY. Chest, 2007, 132, 428C.	0.8	1
26	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.5	0
27	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30.	0.5	0
28	Clinical characterization of patients with interstitial lung disease: Report from a single Canadian Center. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 310-315.	0.5	0